Larimar Therapeutics Inc (LRMR NASDAQ) stock market data APIs
$4.0249
0.22(5.5%)
as of May 5, 2026
Try our APIs with
free plan!
Larimar Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Prev. Close
4.0249
Open
4.2418
High
4.2961
Low
3.9705
52 wk Range
1.73-6.42
Market Cap
417 M
Shares Outstanding
104 M
EPS
0
Beta
0.912
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Larimar Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Larimar Therapeutics Inc data using free add-ons & libraries
Get Larimar Therapeutics Inc Fundamental Data
Larimar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -172 147 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Larimar Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.4815
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Larimar Therapeutics Inc News
New
2 Companies Tackling the AI Bottlenecks
Tom Yeung here with your Sunday Digest. Last week, I wrote about two “future-proof” stocks to help shield your portfolio against the threats of AI. Artificial intelligence was causing mayhem in t...
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Shares of Larimar Therapeutics LRMR rose 55% in the past month after the company announced key regulatory updates related to nomlabofusp, its lead pipeline asset. Larimar outlined upcoming milestones ...
Larimar Therapeutics price target raised to $12 from $11 at Wedbush
Wedbush raised the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $11 and keeps an Outperform rating on the shares. The firm notes that last week, the company completed an upsized $1...
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rar...
Get Larimar Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
